Enterprise Value

103.4M

Cash

123.4M

Avg Qtr Burn

-8.839M

Short % of Float

0.43%

Insider Ownership

0.00%

Institutional Own.

3.56%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2/3

Data readout

Eftilagimod Alpha Details
Cancer, Soft tissue sarcoma

Phase 2

Data readout

Phase 2

Data readout

Phase 1

Data readout

Failed

Discontinued